McKesson Corporation vs Silvercorp Metals Inc. Common Shares — how do they compare? McKesson Corporation trades at $983.95 (market cap $112.15B), while Silvercorp Metals Inc. Common Shares trades at $9.5 (market cap $2.21B). The key difference: McKesson Corporation is far larger — about 50.7× Silvercorp Metals Inc. Common Shares's market cap, and McKesson Corporation pays the higher dividend (0.39%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Silvercorp Metals Inc. Common Shares for 0 Days on average.
| MCK | SVM | |
|---|---|---|
Market Cap | $112.15B | $2.21B |
Volume | 743,618 | 1,113,327 |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $15.71 |
52-Week Low | $725.17 | $6.09 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $118.68B | $1.94B |
Dividend Yield | 0.39% | 0.25% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $976.57, up 2.18% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth from $309B to $359B annually. Recent news highlights the CVS Health partnership extension through 2032, reinforcing distribution stability. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $978.
Outlook remains positive given earnings momentum and strategic partnerships, though valuation at 25.8x P/E and thin 1.12% net margins pose risks. Analysts maintain 80.65% buy ratings with $956 consensus target, slightly below current price. Key risks include drug pricing pressure and macroeconomic sensitivity. Institutional accumulation supports medium-term upside if execution continues.
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →